ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key...
Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group
SYDNEY, Oct. 20, 2025 /PRNewswire/ -- The Brattle Group has welcomed Dr. Luke Wainscoat to its growing Sydney office as a Principal in the firm's Antitrust & Competition practice. An economist with 20 years of experience, Dr. Wainscoat advises...
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the...
Webull Reduces Minimum ASX Trading Fee To $1
Webull Australia now offers the lowest-cost CHESS-sponsored brokerage fee minimums for trading ASX shares The new pricing structure is paired with Webull's industry-leading technology and free live pricing data $1.00 minimum fees will be made...
Yaber Expands Its Global Footprint -- Now Available at JB Hi-Fi Across Australia
SYDNEY, Oct. 20, 2025 /PRNewswire/ -- Yaber, a pioneer of entertainment projectors, now announces its official entry into JB Hi-Fi, one of Australia's largest home entertainment retailers. This marks another milestone in Yaber's global expansion,...
Razor Labs Expands Predictive Maintenance Coverage in Australia with Mobile Fleet AI Solution Launch at IMARC 2025
The company introduces its proven Mobile Fleet Predictive Maintenance solution to Australia, completing its full-suite offering for mining reliability. SYDNEY, Oct. 20, 2025 /PRNewswire/ -- Razor Labs (TASE: RZR), a global leader in AI-driven...
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a...
HARMONi-6 dаta: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged...